Novo Nordisk Unveils Bold 2030 Vision: The Next Generation of Weight Loss and Diabetes Breakthroughs
The pharmaceutical giant Novo Nordisk has revealed an ambitious growth strategy aimed at dominating metabolic health by 2030. With the development of new 'blockbuster' drugs like CagriSema and a massive shift toward oral medications, the company seeks to revolutionize how millions treat obesity and diabetes worldwide, ensuring a hopeful future for global healthcare.